Talessa Powell, MD
Family Medicine · Greenfield, INNPI 1629162987
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. Novo Nordisk AS accounts for 63.7% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2019 at $2,252 and has fallen 95.8% since, to $94 in 2025.
Across 62 payments — averaging $45.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk AS$2K
- GSK$177
- Lilly USA, LLC$142
- Novo Nordisk$131
- Biohaven Pharmaceuticals, Inc.$124
- Johnson & Johnson$83
- plus $360 from 10 others
Across 559 payments — averaging $2643.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$980K
- Novo Nordisk AS$488K
- Boehringer Ingelheim$8K
- Boehringer Ingelheim International GmbH$372
What the payments were for
- Travel & lodging$1,20943%
- Food & beverage$1,58457%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk AS | 4 | $1,783 |
| GSK | 10 | $177 |
| Lilly USA, LLC | 10 | $142 |
| Novo Nordisk | 10 | $131 |
| Biohaven Pharmaceuticals, Inc. | 1 | $124 |
| Johnson & Johnson | 2 | $83 |
| Exact Sciences | 4 | $75 |
| AstraZeneca | 5 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $49 |
| Boehringer Ingelheim | 3 | $47 |
| Pfizer | 3 | $43 |
| Sanofi-aventis U.S. LLC | 2 | $22 |
| Novartis | 1 | $17 |
| Abbott | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $14 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$124
How this compares
$2,801 in reported general payments places this provider in the 75th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $75,662 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 47 | $59,554 |
| TrulicityDulaglutide | 38 | $46,257 |
| MounjaroTirzepatide | 30 | $43,888 |
| EliquisApixaban | 33 | $43,449 |
| RybelsusSemaglutide | 30 | $42,814 |
| XareltoRivaroxaban | 26 | $36,332 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $32,787 |
| OzempicSemaglutide | 21 | $32,504 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $32,262 |
| MyrbetriqMirabegron | 48 | $31,504 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $21,339 |
| Spiriva RespimatTiotropium Bromide | 27 | $19,050 |
| JanuviaSitagliptin Phosphate | 19 | $17,160 |
| FarxigaDapagliflozin Propanediol | 14 | $17,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $47 | $94,712105 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $142 | $90,14468 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Shingrix | $177 | $86,435149 claims |
| Novo NordiskRybelsus, Ozempic | $131 | $75,31851 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $22 | $59,55447 claims |
| PfizerEliquis, Abrysvo | $43 | $47,28745 claims |
| Johnson & JohnsonXarelto | $83 | $36,33226 claims |
| AstraZenecaFarxiga, Symbicort, Breztri Aerosphere | $63 | $34,54952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Greenfield
- Richard TannerIndianapolis$1.6M
- James AndryBloomington$715K
- Richard FeldmanIndianapolis$476K
- Anthony InzerelloEvansville$308K
- Joe BanksIndianapolis$294K
- Steven GatewoodElwood$281K
- Shekar PushpalaCarmel$239K
- Victoria MoyerKokomo$188K
- Thomas KintanarFort Wayne$185K
- Jeffrey HiltzMuncie$177K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.